Vol 59, No 2 (2021)
Original paper
Published online: 2021-06-07
Identification of circulating regulatory T lymphocytes with membrane markers — a new multiparameter flow cytometry protocol
1
, 23, 4, 4, 5, 23
, 23, 4, 4, 5, 23
Abstract
Introduction. Regulatory T cells (Tregs) are a unique CD4+ T cell subset involved in the regulation of immune responses. The traditional immunophenotype used to define Tregs includes CD4+CD25high and the expression of the transcription factor Forkhead box protein 3 (FoxP3). A complex technique of intracellular staining, transient upregulation of FoxP3 in activated conventional T lymphocytes (Tcons), and the omission of naïve CD45RA+ Tregs with downregulated FoxP3 activity but a demethylated FOXP3 promoter region may lead to inaccurate quantification. In an attempt to meet the need for a reliable and simplified enumeration strategy, we investigated different membrane markers to capture the entire Treg compartment and to identify subpopulations of Tregs.
Material and methods. Analyses were performed on whole blood. Tested gating strategies were based on the expression of the following membrane antigens: CD45, CD3, CD4, CD25, CD127, CD26, CD6, CD39, CD71, HLA-DR, CD45RA and CD31. Double controls with FoxP3 were performed.
Results. The final enumeration panel consisted of the membrane markers CD45, CD3, CD4, CD25, CD127, CD26, CD39, CD45RA and CD31. A deep analysis of T cells with the CD4+CD25+CD127low/-CD26low/-CD45RAimmunophenotype revealed high expression of FoxP3 and/or CD39, while cells with the naïve immunophenotype, CD4+CD25+CD127low/-CD26low/-CD45RA+, presented lower expression of suppressor markers. Antigen CD31 is considered to be a valuable membrane marker of thymus-derived Tregs.
Conclusions. The presented 9-color panel that can be easily applied in laboratories enables reliable enumeration of Tregs with additional information about the functionality, maturity and origin of T regulatory cells.
Keywords: T regulatory cellsenumerationflow cytometry9-color panelCD31
References
- Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003; 112(11): 1688–1696.
- Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008; 133(5): 775–787.
- Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006; 107(8): 3074–3080.
- Gorgun G, Miller KB, Foss FM, et al. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transplant. 2002; 29(9): 719–725.
- Rubegni P, Sbano P, Cevenini G, et al. CD4+CD25+ lymphocyte subsets in chronic graft versus host disease patients undergoing extracorporeal photochemotherapy. Int J Immunopathol Pharmacol. 2007; 20(4): 801–807.
- Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation. 2007; 84(1): 31–39.
- Schmitt S, Johnson TS, Karakhanova S, et al. Extracorporeal photophoresis augments function of CD4+CD25+FoxP3+ regulatory T cells by triggering adenosine production. Transplantation. 2009; 88(3): 411–416.
- Gao W, Lu Y, El Essawy B, et al. Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen-specific regulatory T cells. Am J Transplant. 2007; 7(7): 1722–1732.
- Jedlickova Z, Burlakova I, Bug G, et al. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors. Biol Blood Marrow Transplant. 2011; 17(5): 657–663.
- Teshima T. JAK inhibitors: a home run for GVHD patients? Blood. 2014; 123(24): 3691–3693.
- Zeiser R, Nguyen VuH, Beilhack A, et al. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006; 108(1): 390–399.
- Di Biaso I, Di Maio L, Bugarin C, et al. Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. Transplantation. 2009; 87(9): 1422–1425.
- Hardy MY, Vari F, Rossetti T, et al. A flow cytometry based assay for the enumeration of regulatory T cells in whole blood. J Immunol Methods. 2013; 390(1-2): 121–126.
- Fazekas de St Groth B, Zhu E, Asad S, et al. Flow cytometric detection of human regulatory T cells. Methods Mol Biol. 2011; 707: 263–279.
- Pitoiset F, Barbié M, Monneret G, et al. A standardized flow cytometry procedure for the monitoring of regulatory T cells in clinical trials. Cytometry B Clin Cytom. 2018; 94(5): 621–626.
- Pitoiset F, Cassard L, El Soufi K, et al. Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses. Cytometry A. 2018; 93(8): 793–802.
- d'Hennezel E, Piccirillo CA. Analysis of human FOXP3+ Treg cells phenotype and function. Methods Mol Biol. 2011; 707: 199–218.
- Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006; 203(7): 1693–1700.
- Klein S, Kretz CC, Krammer PH, et al. CD127(low/-) and FoxP3(+) expression levels characterize different regulatory T-cell populations in human peripheral blood. J Invest Dermatol. 2010; 130(2): 492–499.
- Yu N, Li X, Song W, et al. CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood. Inflammation. 2012; 35(6): 1773–1780.
- Hartigan-O'Connor DJ, Poon C, Sinclair E, et al. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J Immunol Methods. 2007; 319(1-2): 41–52.
- Arroyo Hornero R, Betts GJ, Sawitzki B, et al. CD45RA Distinguishes CD4+CD25+CD127-/low TSDR Demethylated Regulatory T Cell Subpopulations With Differential Stability and Susceptibility to Tacrolimus-Mediated Inhibition of Suppression. Transplantation. 2017; 101(2): 302–309.
- Seddiki N, Santner-Nanan B, Tangye SG, et al. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood. 2006; 107(7): 2830–2838.
- Nettenstrom L, Alderson K, Raschke EE, et al. An optimized multi-parameter flow cytometry protocol for human T regulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic analysis, and comparison of cord and adult blood. J Immunol Methods. 2013; 387(1-2): 81–88.
- Mandapathil M, Lang S, Gorelik E, et al. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods. 2009; 346(1-2): 55–63.
- Garcia Santana CA, Tung JW, Gulnik S. Human treg cells are characterized by low/negative CD6 expression. Cytometry A. 2014; 85(10): 901–908.
- Salgado FJ, Pérez-Díaz A, Villanueva NM, et al. CD26: a negative selection marker for human Treg cells. Cytometry A. 2012; 81(10): 843–855.
- Douaisi M, Resop RS, Nagasawa M, et al. CD31, a Valuable Marker to Identify Early and Late Stages of T Cell Differentiation in the Human Thymus. J Immunol. 2017; 198(6): 2310–2319.
- Motamedi M, Xu L, Elahi S. Correlation of transferrin receptor (CD71) with Ki67 expression on stimulated human and mouse T cells: The kinetics of expression of T cell activation markers. J Immunol Methods. 2016; 437: 43–52.
- Sprangers B, DeWolf S, Savage TM, et al. Origin of Enriched Regulatory T Cells in Patients Receiving Combined Kidney-Bone Marrow Transplantation to Induce Transplantation Tolerance. Am J Transplant. 2017; 17(8): 2020–2032.
- Tanaka A, Sakaguchi S, Tanaka A, et al. Regulatory T cells in cancer immunotherapy. Cell Res. 2017; 27(1): 109–118.
- Curotto de Lafaille MA, Kutchukhidze N, Shen S, et al. Adaptive Foxp3+ regulatory T cell-dependent and -independent control of allergic inflammation. Immunity. 2008; 29(1): 114–126.
- Horwitz DA, Zheng SG, Gray JD. Natural and TGF-beta-induced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008; 29(9): 429–435.
- Abbas AK, Benoist C, Bluestone JA, et al. Regulatory T cells: recommendations to simplify the nomenclature. Nat Immunol. 2013; 14(4): 307–308.
- Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001; 193(11): 1303–1310.
- Kleinewietfeld M, Starke M, Di Mitri D, et al. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood. 2009; 113(4): 827–836.
- Silva SL, Albuquerque AS, Serra-Caetano A, et al. Human naïve regulatory T-cells feature high steady-state turnover and are maintained by IL-7. Oncotarget. 2016; 7(11): 12163–12175.
- Imanguli MM, Cowen EW, Rose J, et al. Comparative analysis of FoxP3(+) regulatory T cells in the target tissues and blood in chronic graft versus host disease. Leukemia. 2014; 28(10): 2016–2027.
- Silva SL, Sousa AE. Establishment and Maintenance of the Human Naïve CD4 T-Cell Compartment. Front Pediatr. 2016; 4: 119.
- Willasch AM, Salzmann-Manrique E, Krenn T, et al. Advanced flowcytometric analysis of regulatory T cells: CD127 downregulation early post stem cell transplantation and altered Treg/CD3(+)CD4(+)-ratio in severe GvHD or relapse. J Immunol Methods. 2011; 373(1-2): 36–44.
